JP2025508867A5 - - Google Patents
Info
- Publication number
- JP2025508867A5 JP2025508867A5 JP2024550555A JP2024550555A JP2025508867A5 JP 2025508867 A5 JP2025508867 A5 JP 2025508867A5 JP 2024550555 A JP2024550555 A JP 2024550555A JP 2024550555 A JP2024550555 A JP 2024550555A JP 2025508867 A5 JP2025508867 A5 JP 2025508867A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence number
- cdrl1
- cdrl2
- cdrl3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22159045 | 2022-02-27 | ||
| EP22159045 | 2022-02-27 | ||
| EP22162761 | 2022-03-17 | ||
| EP22162761 | 2022-03-17 | ||
| EP23157433 | 2023-02-19 | ||
| EP23157433 | 2023-02-19 | ||
| PCT/EP2023/054762 WO2023161457A1 (en) | 2022-02-27 | 2023-02-26 | Bispecific antibodies against cd277 and a tumor-antigen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508867A JP2025508867A (ja) | 2025-04-10 |
| JP2025508867A5 true JP2025508867A5 (https=) | 2026-03-04 |
Family
ID=85382872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024550555A Pending JP2025508867A (ja) | 2022-02-27 | 2023-02-26 | Ｃｄ２７７と腫瘍抗原に対する二重特異性抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250163157A1 (https=) |
| EP (1) | EP4482859A1 (https=) |
| JP (1) | JP2025508867A (https=) |
| KR (1) | KR20240149438A (https=) |
| CN (1) | CN119173528A (https=) |
| CA (1) | CA3243624A1 (https=) |
| IL (1) | IL314678A (https=) |
| MX (1) | MX2024010485A (https=) |
| WO (1) | WO2023161457A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024074498A1 (en) | 2022-10-04 | 2024-04-11 | Imcheck Therapeutics | Combination of a btn3a activating antibody, a bcl2 inhibitor and hypomethylating agent for use in treating cancer |
| IL322506A (en) | 2023-02-23 | 2025-10-01 | Imcheck Therapeutics | Combinations of BTN3A activating antibody and immune checkpoint inhibitors |
| TW202506731A (zh) | 2023-04-27 | 2025-02-16 | 法商感應檢查療法公司 | 治療多重抗藥性細菌感染之方法 |
| EP4731681A1 (en) | 2023-06-23 | 2026-04-29 | Imcheck Therapeutics | Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| BRPI0717638A2 (pt) | 2006-10-27 | 2013-11-12 | Genentech Inc | Anticorpors e imunoconjugados e usos para os mesmos |
| EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| EP3002296B1 (en) | 2009-03-17 | 2020-04-29 | Université d'Aix-Marseille | Btla antibodies and uses thereof |
| CA2756244A1 (en) | 2009-04-02 | 2010-10-07 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
| BR112012007875A2 (pt) | 2009-07-31 | 2016-11-22 | Medarex Inc | anticorpos totalmente humanos para btla |
| WO2012080769A1 (en) | 2010-12-15 | 2012-06-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-cd277 antibodies and uses thereof |
| US20150353643A1 (en) | 2013-09-24 | 2015-12-10 | Universite De La Mediterranee - Aix-Marseille Ii | Anti-cd277 antibodies and uses thereof |
| JP2014508165A (ja) | 2011-03-02 | 2014-04-03 | モルフォテック、インク． | 乳癌の治療のためのエリブリンおよびファーレツズマブの共投与 |
| WO2013174403A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| RS63738B1 (sr) | 2013-02-20 | 2022-12-30 | Astellas Pharma Inc | Kombinovana terapija koja uključuje antitela protiv klaudina 18.2 za lečenje kancera |
| WO2014127785A1 (en) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014165818A2 (en) | 2013-04-05 | 2014-10-09 | T Cell Therapeutics, Inc. | Compositions and methods for preventing and treating prostate cancer |
| PT3221356T (pt) | 2014-11-20 | 2020-10-29 | Hoffmann La Roche | Moléculas de ligação ao antigénio biespecíficas ativadoras das células t contra folr1 e cd3 |
| JP2018533930A (ja) | 2015-10-02 | 2018-11-22 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性ｔ細胞活性化抗原結合分子 |
| MX2018010295A (es) | 2016-02-26 | 2019-06-06 | Inst Nat Sante Rech Med | Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos. |
| IL303187A (en) | 2016-08-29 | 2023-07-01 | Akamis Bio Ltd | Adenovirus with bispecific T cell activator |
| EP3773676A4 (en) | 2018-04-03 | 2022-05-18 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams |
| WO2019211370A1 (en) | 2018-05-03 | 2019-11-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cancer |
| MX2021001268A (es) | 2018-08-01 | 2021-09-08 | Imcheck Therapeutics Sas | Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos. |
| AU2019344300A1 (en) | 2018-09-19 | 2021-04-22 | LAVA Therapeutics N.V. | Dual acting CD1D immunoglobulin |
| CN119080930A (zh) | 2019-07-11 | 2024-12-06 | 纪念斯隆凯特琳癌症中心 | Dll3靶向抗体及其用途 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| PH12022553489A1 (en) | 2020-06-19 | 2024-04-22 | Hoffmann La Roche | Antibodies binding to cd3 and folr1 |
-
2023
- 2023-02-26 EP EP23707379.6A patent/EP4482859A1/en active Pending
- 2023-02-26 WO PCT/EP2023/054762 patent/WO2023161457A1/en not_active Ceased
- 2023-02-26 US US18/841,269 patent/US20250163157A1/en active Pending
- 2023-02-26 CA CA3243624A patent/CA3243624A1/en active Pending
- 2023-02-26 CN CN202380030646.1A patent/CN119173528A/zh active Pending
- 2023-02-26 JP JP2024550555A patent/JP2025508867A/ja active Pending
- 2023-02-26 IL IL314678A patent/IL314678A/en unknown
- 2023-02-26 KR KR1020247031819A patent/KR20240149438A/ko active Pending
-
2024
- 2024-08-26 MX MX2024010485A patent/MX2024010485A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025508867A5 (https=) | ||
| JP2021534096A5 (https=) | ||
| JP2018108081A5 (https=) | ||
| JP2022548783A5 (https=) | ||
| JP2021533159A5 (https=) | ||
| HRP20240626T1 (hr) | Bispecifična antitijela protiv ceacam5 i cd3 | |
| JP2024541680A5 (https=) | ||
| JP2006512899A5 (https=) | ||
| JP2017529838A5 (https=) | ||
| JP2017512765A5 (https=) | ||
| JP2014158469A5 (https=) | ||
| JP2022540083A5 (https=) | ||
| JP2024542194A5 (https=) | ||
| JP2011207882A5 (https=) | ||
| TW201026325A (en) | Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment | |
| JP2024016024A5 (https=) | ||
| JP2025032102A5 (https=) | ||
| JP2020500834A5 (https=) | ||
| JP2025128343A5 (https=) | ||
| JP2024109911A5 (https=) | ||
| JP2022507253A5 (https=) | ||
| JP2025092589A5 (https=) | ||
| JP2024504390A5 (https=) | ||
| JP2022545741A5 (https=) | ||
| JP2023518153A5 (https=) |